{"id":"W4412974237","doi":"10.1158/2767-9764.crc-25-0019","title":"Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; University of Alberta; Spinal Cord Injury BC; Ontario Institute for Cancer Research; Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Merck Canada; National Cancer Institute; Incyte; Memorial Sloan-Kettering Cancer Center; BeiGene; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002548602,0.0001411174,0.0005243769,0.0008841634,0.0002263089,0.00003486477,0.0011699,0.00003830449,0.0002212017],"category_scores_gemma":[0.001034241,0.0001196193,0.00004183817,0.00311514,0.0007372815,0.00009283978,0.0006501411,0.001190401,0.00001980137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007083077,"about_ca_system_score_gemma":0.003181258,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00673787,"about_ca_topic_score_gemma":0.01371513,"domain_scores_codex":[0.9961445,0.00114641,0.000599507,0.0003440523,0.001045126,0.0007204466],"domain_scores_gemma":[0.9949199,0.0009438841,0.000080255,0.002922158,0.0009163863,0.0002173915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01223605,0.1127473,0.5958285,0.003792186,0.003078194,0.0005054843,0.04623969,0.001038629,0.04506743,0.009815471,0.0203794,0.1492717],"study_design_scores_gemma":[0.1806875,0.04287939,0.4033544,0.02201522,0.001381813,0.00004467041,0.1678184,0.03963493,0.07368363,0.004258465,0.06242079,0.001820699],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814256,0.003045876,0.00003148985,0.006254094,0.00002559413,0.002686421,0.00003329726,0.00002864828,0.006468934],"genre_scores_gemma":[0.9949704,0.0009516813,0.0004250306,0.00008557334,0.00001332298,0.002453374,0.00001497533,0.0000284233,0.001057221],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1924741,"threshold_uncertainty_score":0.9998763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3892141963931314,"score_gpt":0.6154104701398585,"score_spread":0.2261962737467271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}